How to read an oncological biopsy: Practical guide for patients and implications for therapy

You’ve received your biopsy results, read the first line, and already it feels like the pages are written in another language. Terms like “moderately differentiated adenocarcinoma, pT2 pN1 M0, margins R0, Ki-67 35%” seem like an impossible code to crack. If you’re in this situation, know that you’re not alone — thousands of patients go through the same moment of confusion and anxiety every day.

The good news is that the histopathology report follows a logical and repeatable structure . Once you understand what each section means, you will not only know how to read the document, but you will be able to have a much more informed conversation with your oncologist and understand why certain treatments are recommended for you and not others.

This guide translates the most important terms from the biopsy result into simple words, explaining step by step what tumor grading , pTNM code , resection margins , and immunohistochemical profile mean — and, most importantly, how each of these parameters directly influences the therapeutic decision.

1. What is the histopathology report?

A biopsy is a procedure in which a doctor removes a small sample of tissue from a suspicious area. This sample is sent to a pathology laboratory, where a specialized doctor— a pathologist —examines it carefully under a microscope.

The histopathology report is the final document you receive: it contains the microscopic conclusion of that analysis. Unlike a blood test or an ultrasound, a biopsy provides certainty — the doctor actually sees the cells, compares them to normal cells, and can tell precisely what type of tumor it is, how aggressive it is, and how far it has spread.

2. What does Histological Type (Tumor Name) mean?

The first major piece of information in the report is the histological type — basically, the “name” of the cancer, based on the cells it started from. Here are the most common names:

Adenocarcinoma : Cancer that starts in glandular cells. It is the most common type in the breast, colon, prostate, and lungs (the non-smoking form).
Squamous cell (epidermoid) carcinoma : Occurs in the flat cells that line surfaces — skin, oral cavity, larynx, cervix, lungs (smoker’s form).
Sarcoma : Cancer of the supporting tissues—bone, muscle, cartilage, fat. Less common than carcinomas.
Lymphoma : Cancer that starts in immune system cells, located in the lymph nodes or spleen.

Why does it matter for treatment? Because the therapeutic regimen depends fundamentally on the histological type. A HER2-positive breast adenocarcinoma will be treated completely differently than a squamous cell carcinoma of the lung. The oncologist cannot choose the correct protocol without this basic information.

3. Tumor Grading (G Score): How aggressive are the cells?

Once the tumor type is determined, the pathologist evaluates the degree of cellular differentiation — denoted by the letter G in the report. This measures how much more similar the cancer cells are to the normal cells from which they originated.

The simple rule: the more similar the cells are to normal cells, the slower the tumor grows. The more different they are, the more aggressive they are.

G1 — Well-Differentiated (Low Grade) : The tumor cells look almost identical to normal cells. The tumor is slow-growing, the least aggressive, and has a low risk of spreading quickly.
G2 — Moderately differentiated (Intermediate grade) : The cells have begun to lose their normal appearance, showing visible abnormalities. Medium aggressiveness.
G3 — Poorly differentiated (High grade) : Cells look very different from normal and multiply rapidly. High risk of local invasion and metastasis.
G4 — Undifferentiated : The cells are so altered that it is difficult to even determine the organ of origin. The most aggressive type.

Treatment implications : A G1 may be a candidate for active surveillance or single surgery. A G3 or G4 almost always requires combination treatments—chemotherapy, radiation therapy, or targeted therapies—to control the risk of spread.

4. pTNM classification: How is the stage of cancer determined?

TNM system is the international standard used by oncologists around the world to describe the extent of a cancer. The lowercase “p” in front (pTNM) means that the information has been confirmed pathologically , i.e. under a microscope, after surgery — it’s not just estimates from CT or MRI scans, but absolute certainties.

pT — Primary Tumor

Describe the size and depth of invasion of the main tumor:

pTis (carcinoma in situ): The earliest stage — cancer cells have not invaded deeply.
pT1 : Small, localized tumor.
pT2 / pT3 : Tumor of larger size or that has invaded neighboring structures.
pT4 : Extensive tumor, which has reached surrounding vital organs or structures.

pN — Regional Lymph Nodes

It shows whether cancer cells have migrated to the body’s “filter stations”:

pN0 : No cancer cells were found in the lymph nodes — an excellent sign.
pN1 / pN2 / pN3 : The increased number of affected nodes reflects a more extensive extension.

pM — Distant Metastases

pM0 : No evidence of spread to distant organs (lungs, liver, bones, brain).
pM1 : The cancer has spread distantly — stage IV or metastatic.

Implications for therapy : The correlation of the three letters allows the oncologist to establish the final stage (I, II, III or IV) and decide whether adjuvant chemotherapy, radiotherapy or hormonal therapy is necessary after surgery to prevent a relapse. For example, a pT2 pN0 M0 has an excellent prognosis and often does not require chemotherapy, while a pT3 pN2 M0 will almost certainly require adjunctive treatment.

5. Resection Margins: Are They Clean or Invaded?

When the surgeon removes a tumor, he or she also removes a margin of healthy tissue around it— the safety margin . The pathologist then examines the cut line to see if there are any cancer cells left.

R0 — Negative margins (free/clean) : The best possible news after surgery. Only healthy cells are found at the outer edge of the removed piece. The surgeon was able to completely remove the tumor.
R1 — Microscopically positive margins (invaded) : Under a microscope, the cut line goes right through the cancer cells. There is a risk that microscopic fragments of the tumor remain in the body.
R2 — Macroscopically positive margins : A visible portion of the tumor could not be removed during surgery — usually because of proximity to a major blood vessel or vital organ.

Direct implications in therapy : R1 or R2 margins immediately change the therapeutic plan. The medical team will almost always recommend local radiotherapy to destroy residual cells or even a surgical reintervention , associated with systemic therapies (chemotherapy or hormonal therapy).

6. Immunohistochemical (IHC) Profile: The Key to Personalized Treatment

If the basic biopsy says “what” cancer is, the immunohistochemical (IHC) profile says “how to treat it .” It is the test that transforms oncology from a general science into truly personalized medicine.

With IHC, the laboratory applies special “stains” to the tissue to detect the presence or absence of specific proteins on the surface of cancer cells. The most important markers are:

Hormone Receptors (ER and PR) — common in breast and endometrial cancer. If the tumor is ER+ or PR+ , hormones fuel the cancer, but the good news is that these tumors respond well to hormonal therapy (tamoxifen, aromatase inhibitors).
HER2 protein — critical marker in breast and gastric cancer. A HER2 3+ tumor is more aggressive, but can be fought very effectively with modern targeted therapies (trastuzumab/pertuzumab).
The Ki-67 marker — expressed as a percentage, shows how many cells in the tumor are actively dividing. Ki-67 below 15–20% = slow-growing tumor; Ki-67 above 30–40% = fast-dividing, aggressive tumor — but which, paradoxically, responds better to chemotherapy.
PD-L1 marker — assesses whether the tumor is “hiding” from the immune system. A high value indicates that the patient is an excellent candidate for next-generation immunotherapy .

7. How Does Artificial Intelligence Help in Biopsy Interpretation?

The IHC profile generates a huge amount of combinations and data. International treatment protocols (NCCN / ESMO) are constantly updated based on new clinical studies. No patient can track all these changes alone.

the Oncoexpert AI platform comes in . Our advanced Artificial Intelligence algorithms correlate all the parameters in your histopathology report — histological type, grading, pTNM stage, margin status and complete IHC profile — with thousands of international clinical studies and oncology guidelines updated in real time. The technology does not replace the doctor, but gives the patient the certainty that the proposed therapeutic regimen is supported by the latest global scientific evidence .

📂 Have you received your biopsy report and want to understand it better? Upload your medical file to Oncoexpertai.com and receive an informed second opinion, based on international NCCN and ESMO protocols, assisted by Artificial Intelligence.

Disclaimer: The information in this article is for informational and educational purposes only. It is not a medical document, does not replace the consultation of a specialist doctor, and does not constitute a diagnosis. Any therapeutic decision should be made exclusively after consultation with your medical team.

Bibliography

World Health Organization. WHO Classification of Tumours: Digestive System Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
World Health Organization. WHO Classification of Tumours: Breast Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer Staging Manual. 8th ed. Cham: Springer; 2017.
Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley Blackwell; 2017.
College of American Pathologists. Cancer Protocols and Templates. Northfield, IL: College of American Pathologists. Disponibil la: https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Plymouth Meeting, PA: NCCN. Disponibil la: https://www.nccn.org/guidelines
European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Lugano: ESMO. Disponibil la: https://www.esmo.org/guidelines
Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 2018;36(20):2105–2122.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology. 2020;38(12):1346–1366.
Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute. 2011;103(22):1656–1664.
Cree IA, Tan PH, Travis WD, et al. Counting mitoses: SI(ze) matters! Modern Pathology. 2021;34:1651–1657.
Hendry S, Byrne DJ, Wright GM, et al. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. Journal of Thoracic Oncology. 2018;13(3):367–376.
Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2020.
Rubin R, Strayer DS, Rubin E, editors. Rubin’s Pathology: Clinicopathologic Foundations of Medicine. 7th ed. Philadelphia: Wolters Kluwer; 2018.
DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 12th ed. Philadelphia: Wolters Kluwer; 2023.

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI

Onisim Florin

Login